Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that for the January - May 2009 time period, a significantly higher percentage of hetastarch recipients (75%) underwent a surgical procedure when compared to those receiving albumin/plasma protein fraction (51%). Hetastarch, albumin and plasma protein fraction are plasma expanders that are mainly used in hospital patients to replace fluid in cases of severe shock, as may occur with blood or fluid loss during surgery.

The newly released U.S. edition of the Plasma Expander Hospital Inpatient Profile Study also finds that albumin 25% is most often administered to patients with liver disease and hypotension/shock due to infection or surgical blood loss. Similarly, albumin and plasma protein fraction 5% are most often administered to patients with hypotension/shock from surgical blood loss, cardiogenic hypotension/shock and cardiopulmonary bypass procedures.

AMR's new Plasma Expander Hospital Inpatient Profile Study clinically characterizes U.S. hospital inpatient recipients of plasma expanders such as albumin, plasma protein fraction and hetastarch to identify relative usage patterns by indication, patient age and sex, prescribing physician specialty, dosing and primary method of payment.

"The new Plasma Expander Hospital Inpatient Profile Study is a nice complementary study to our Plasma Expander Hospital Purchasing Audit," stated Mary Walker, R.Ph., MBA, therapeutics principal director at AMR. "While the Purchasing Audit enables pharmaceutical companies to monitor the market size, market potential or market influences of plasma expanders, the Inpatient Profile Study allows these same companies to monitor plasma expander users and prescribers."

Why Pharmaceutical Companies Need this Information

The Plasma Expander Hospital Inpatient Profile Study enables pharmaceutical companies to monitor patient shares, prescribing physician specialty, dosing and payment method of plasma expander use in the hospital setting.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:     Gisselle Morales                             Elizabeth Marshall   Decision Resources                           Decision Resources, Inc.   781-296-2691                                 781-296-2563   gmorales@dresources.com                      emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Arlington Medical Resources

CONTACT: Gisselle Morales of Decision Resources, +1-781-296-2691,
gmorales@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018

View Now